期刊文献+

探讨TyG、SAA在动脉粥样硬化中的预测价值

To Investigate the Predictive Value of TyG and SAA in Atherosclerosis
下载PDF
导出
摘要 动脉粥样硬化是一种对人体危害较大的慢性心脑血管疾病;合并高血压、糖尿病除了导致下肢血管缺血跛行、下肢血管闭塞缺血性溃疡和截肢外,更重要的是这些患者心血管事件的风险明显增加,死亡率更高,主要死亡原因是心血管事件。脂代谢异常胰岛素抵抗和炎症反应导致血管内皮受损是动脉粥样硬化发生和发展的核心机制,不良生活习惯、年龄、糖尿病病程、血糖、血压、肥胖(尤其是腹型肥胖)、血脂、尿酸、环境污染物等,这些都加速动脉粥样硬化进展,导致肾功能减退和患者全因死亡风险增加显著,这篇综述阐述了导致动脉粥样硬化发生的影响因素及作用机制, 探讨了TyG、SAA在动脉粥样硬化中的潜在作用。 Atherosclerosis is a kind of chronic cardio-cerebrovascular disease which is harmful to human body. In addition to lower extremity ischemic claudication, lower extremity vascular occlusive ischemic ulcers and amputation, these patients with hypertension and diabetes have a significantly in-creased risk of cardiovascular events and a higher mortality rate, and the main cause of death is cardiovascular events. Abnormal lipid metabolism insulin resistance and inflammation leading to vascular endothelial damage is the core mechanism of the occurrence and development of athero-sclerosis, bad living habits, age, diabetes course, blood sugar, blood pressure, obesity (especially abdominal obesity), lipid, uric acid, environmental pollutants, etc. These accelerate the progression of atherosclerosis, leading to renal decline and a significant increase in the risk of all-cause death in patients. This review describes the influencing factors and mechanism of atherosclerosis, and dis-cusses the potential role of TyG and SAA in atherosclerosis.
出处 《临床医学进展》 2022年第11期10019-10025,共7页 Advances in Clinical Medicine
  • 相关文献

参考文献3

二级参考文献9

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 2Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985,28:412-419.
  • 3Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care, 1998,21:2191-2192.
  • 4Turner RC, Levy JC, Rudesnki AS, et al. Measurement of insulin resistance and β-cell function: the HOMA and CIGMA approach. In: Belfiore F, et al (eds). Current topics in diabetes research, Front Diabetes (12). Basel, Karger, 1993,66-75.
  • 5Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004,27:1487-1495.
  • 6Matthews DR. Insulin resistance and β-cell function-a clinical perspective. Diabetes Obes Metab, 2001,3(Suppl 1):S28-S33.
  • 7Hermans MP, Levy JC, Morris RJ, et al. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia, 1999,42:678-687.
  • 8Hermans MP, Levy JC, Morris RJ, et al. Comparison of tests of β -cell function across a range of glucose tolerance from normal to diabetes. Diabetes, 1999,48:1770-1786.
  • 9Jun Sun,Eugene B.Chang.Exploring gut microbes in human health and disease:Pushing the envelope[J].Genes & Diseases,2014,1(2):132-139. 被引量:19

共引文献126

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部